Stockscreener 앱 받기
2.52
1.61%
0.04
시장 영업 전:
2.58
0.06
+2.38%
Acumen Pharmaceuticals Inc 주식(ABOS)의 최신 뉴스
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026 - Weekly Voice
Acumen sets May 12 earnings update, webcast starts at 8 a.m. ET - Stock Titan
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026 - GlobeNewswire Inc.
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increases By 46.4% - MarketBeat
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN
Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders - MSN
Research presented by Acumen Pharmaceuticals explores new approach at AAN meeting - Traders Union
Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding - MSN
Acumen (NASDAQ: ABOS) seeks approval for major equity plan expansion - Stock Titan
[ARS] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
Acumen (ABOS) Stock: Strategic Buy or Not (Eye on Rally) 2026-04-22Shared Momentum Picks - UBND thành phố Hải Phòng
Acumen Pharmaceuticals (NASDAQ:ABOS) Trading 0.7% HigherStill a Buy? - MarketBeat
Aug Selloffs: Is Acumen Pharmaceuticals Inc a strong candidate for buy and hold2026 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
Chart Watch: What is the earnings history of Acumen Pharmaceuticals IncMarket Risk Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug Chart Watch: What is the earnings history of Acumen Pharmaceuticals IncGDP Growth & Short-Term High Return Strategies - baoquankhu1.vn
James B. Murray Jr. discloses 3.61M shares in Acumen Pharmaceuticals (NASDAQ: ABOS) - Stock Titan
ABOS Technical Analysis & Stock Price Forecast - Intellectia AI
Meme Stocks: Is Acumen Pharmaceuticals Inc being accumulated by smart moneyPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
ABOS Technical Analysis | Trend, Signals & Chart Patterns | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure - TipRanks
Acumen Pharmaceuticals (ABOS) loses 33.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q4 2025 Earnings Conference - 富途牛牛
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2025 Earnings Call Transcript - Insider Monkey
[EFFECT] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) registers 10.83M resale shares - Stock Titan
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - finance.yahoo.com
Aug Final Week: Can Acumen Pharmaceuticals Inc reach resistance levels soon - baoquankhu1.vn
Acumen Pharmaceuticals (ABOS) Drops 33.6% Over the Past Month, Reasons Suggest a Potential Turnaround Could Be Imminent - Bitget
ABOS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Should I buy Acumen Pharmaceuticals (ABOS) - Zacks Investment Research
Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Acumen Pharmaceuticals Reports 2025 Financial Results and Advances Alzheimer’s Drug Pipeline with Phase 2 ALTITUDE-AD Study and Enhanced Brain Delivery Program - Minichart
10.8M Acumen shares registered for resale (NASDAQ: ABOS) - stocktitan.net
Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Acumen Pharmaceuticals (NASDAQ: ABOS) details sabirnetug Alzheimer’s program and funding risks - Stock Titan
Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027 - TipRanks
Stifel reiterates Acumen Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Stifel reiterates Acumen Pharmaceuticals stock rating at buy - Investing.com
Acumen Pharmaceuticals 2025 Financial Review - AlphaStreet
Acumen Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from BTIG Research - MarketBeat
Acumen Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
ABOS: ALTITUDE-AD phase II and EBD advances drive robust pipeline and financial momentum - TradingView — Track All Markets
Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
0.14%
0.48%
자본화:
|
볼륨(24시간):